Ablevia

Ablevia is a Vienna-based, preclinical-stage biotechnology company pioneering a novel therapeutic approach for the selective removal of pathogenic antibodies. Its core technology, SADC, utilizes peptide-based compounds designed to bind and neutralize specific, harmful antibodies—such as those causing autoimmune disorders or neutralizing biologic drugs and gene therapy vectors—while sparing the protective immune repertoire. Founded by an MD and a business operations expert, the company operates as a research and development entity seeking partnerships to advance its platform into clinical applications for rare diseases and conditions with high unmet need. Ablevia represents a potential paradigm shift in managing antibody-mediated conditions by moving from broad immunosuppression to targeted antibody clearance.

SADC (Selective Antibody Depletion Compounds) – a proprietary platform for developing peptide-based infusible biologics that selectively bind and remove specific, harmful antibodies (e.g., autoantibodies, anti-drug antibodies) from circulation while sparing the rest of the immune system.

Direct competition in the niche of selective, injectable antibody removal is limited. Broader competition includes non-selective approaches like plasmapheresis and immunoadsorption, and pharmacological approaches like FcRn inhibitors (e.g., efgartigimod, rozanolixizumab), which non-specifically reduce all IgG antibodies. Ablevia's key differentiator is its claimed selectivity for predefined antibody clones.